Cancer-specific information

Prostate Specific Antigen (ng/ml) at presentation:

- Primary Gleason score: 3 | 4 | 5
- Secondary Gleason score: 3 | 4 | 5

Prostate specific antigen level 3-months after date of operation. Any PSA level between 2-4 months postoperatively permissible

- Available: ✔ Unavailable: ☐

Prostate specific antigen level 3-months after date of study entry. For non-operated patients, any PSA level between 2-4 months postoperatively is allowed

- Available: ✔ Unavailable: ☐

Surgeon level of training

- Trainee, not supervised by consultant
- Consultant performed

Pre-operative plan for nerve-sparing

- No recommendation available
- Bilateral nerve sparing
- Unilateral nerve sparing
- Non-nerve sparing

Management

Was an updated prostate MRI obtained prior to surgery?

- Yes
- No

Date of new pre-operative MRI: __/__/____

Re-imaged radiological T-stage prior to surgery

- T1 | T2 | T3 | T4 | Unknown

Re-imaged radiological N-stage prior to surgery

- N0 | N1 | N2 | Unknown

Re-imaged radiological M-stage prior to surgery

- M0 | M1 | Unknown

Operative approach

- Laparoscopic
- Robotic-assisted
- Robotic

Pathological T-stage

- T1 | T2 | T3 | T4 | Unknown

Pathological N-stage

- N0 | N1 | N2/3 | N3 | Unknown

Pathological M-stage

- M0 | M1 | Unknown

Prostate specific antigen level 3 months after date of operation. Any PSA level between 2-4 months postoperatively permissible

- Available: ✔ Unavailable: ☐

Subsequent PSA level 3 months after date of operation. Any PSA level between 2-4 months postoperatively permissible

- Available: ✔ Unavailable: ☐

Urgency of surgery

- Immediate
- Urgent
- Expeditious
- Elective

Anesthesia type:

- Local
- Regional
- General

Operation

- Pelvic lymph node dissection performed?

- Extended: ✔ Standard: ☐ Not performed

Operative approach

- Open: ✔ Minimally-invasive: ☐ Minimally-invasive converted to open

Minimally invasive surgery type

- Laparoscopic: ✔ Robotic-assisted: ☐

Cause of death whilst waiting for surgery

- Related to COVID-19 infection
- Unrelated to COVID-19 infection

Change in treatment strategy

- Remain on active surveillance
- Long-term hormone treatment
- Radiotherapy
- Other: ____________________________

Prostate still planned for curative surgery? 12 months after study entry

- Yes
- No

Change in clinical status unrelated to cancer e.g. MI

- Yes
- No

Change of recommendation in society guidelines related to COVID-19

- Yes
- No

Change in choice of operation

- Yes
- No

Interventional radiology procedure performed before surgery where this would not typically have been indicated

- Yes
- No

Operation in an alternative hospital (eg. Freeport)

- Yes
- No

Delay to definitive surgery

- Yes
- No

Change of recommendation in society guidelines related to COVID-19

- Yes
- No

MDT decision to delay surgery due to patient risk

- Yes
- No

No change to care

- Yes
- No

No change to operative approach

- Yes
- No

No change to operative plan for nerve-sparing

- Yes
- No

Radiotherapy

- Yes
- No

Other: ____________________________

NB: Continued on next page

COVID-19 era

- Yes
- No

COVID-19 infection

- Yes
- No

COVID-19 era? Select all that apply

- Patient choice to avoid surgery during COVID-19 pandemic
- MDT decision to delay surgery due to patient risk
- Ongoing neoadjuvant therapy
- No bed/critical care bed/OR/theatre space available
- Change of recommendation in society guidelines related to COVID-19
- Other: __________________________

If no ongoing plan for surgery:

- Patient choice to avoid surgery during pandemic
- MDT decision to delay surgery due to risk to patient
- Disease progression, surgery no longer indicated
- Change in clinical status unrelated to cancer e.g. MI
- Died awaiting surgery
- Change of recommendations in society guidelines
- Change to alternative treatment modality
- Other: __________________________

Other: __________________________

Prostate specific antigen level 3 months after date of operation. Any PSA level between 2-4 months postoperatively permissible

- Available: ✔ Unavailable: ☐

Other: __________________________

NB: Continued on next page
Did any change in this non-operated patient’s treatment occur as a result of the COVID-19 pandemic? In comparison to care in the pre-COVID-19 era

☐ No change to care – cancelled for other reason
☐ Operation cancelled because of COVID-19
☐ Operation delayed because of COVID-19
☐ Change in definitive treatment strategy because of COVID-19
☐ IR procedure performed before or instead of surgery, not typically indicated
☐ Underwent neoadjuvant therapy, not typically indicated
☐ No neoadjuvant therapy given, typically indicated
☐ Underwent longer/more intensive course of neoadjuvant therapy than typically indicated
☐ Underwent shorter/less intensive course of neoadjuvant therapy than typically indicated
☐ Reduced access to staging procedures
☐ Reduced access to staging procedures
☐ Other: ____________________

Has restaging/reimaging of this patient’s cancer been performed? ☐ Yes ☐ No

Estimated date of restaging/reimaging: __/__/____

Restaged clinical or radiological T-stage

<table>
<thead>
<tr>
<th>T1</th>
<th>T2</th>
<th>T3</th>
<th>T4</th>
<th>Unknown</th>
</tr>
</thead>
</table>

Re-imaged T3/4

☐ Suspected T3a (suspected capsular involvement)
☐ Unequivocal T3a (clear radiological evidence of capsular involvement)
☐ T3b or T4 (seminal vesicle involvement)

Restaged clinical or radiological N-stage

<table>
<thead>
<tr>
<th>N0</th>
<th>N1</th>
<th>N2/3</th>
<th>Unknown</th>
</tr>
</thead>
</table>

Restaged clinical or radiological M-stage

<table>
<thead>
<tr>
<th>M0</th>
<th>M1</th>
<th>Unknown</th>
</tr>
</thead>
</table>

Prostate specific antigen level 6 months after date of study entry (ng/ml). For non-operated patients, any PSA level between 5-7 months postoperatively is allowed

☐ Available ☐ Unavailable : ____________________

Prostate specific antigen level 9 months after date of study entry. For non-operated, any PSA level between 8-10 months postoperatively is allowed

☐ Available ☐ Unavailable : ____________________

Prostate specific antigen level 12 months after date of study entry. For non-operated, any PSA level between 11-13 months postoperatively is allowed

☐ Available ☐ Unavailable : ____________________